TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 3, 2005, Pages 147-153

  Camarasa, María José ^a   Velázquez, Sonsoles ^a   San Félix, Ana ^a   Pérez Pérez, María Jesús ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Dimerization; Non nucleoside RT inhibitors; Resistance; Reverse transcriptase; RT; TSAO compounds

Indexed keywords

AMINO ACID; ANTIMETABOLITE; ANTIRETROVIRUS AGENT; PROTEIN P66; PROTEIN SUBUNIT; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; [1 [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA RIBOFURASONYL]THYMINE] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE);

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOMEGALOVIRUS INFECTION; DIMERIZATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME BINDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REBOUND; REVIEW; SIDE EFFECT; STANDARD; TREATMENT FAILURE; VIRUS STRAIN;

EID: 27244439063     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600301     Document Type: Review

References (42)

1. Amacker M & Hübscher U (1998) Chimeric HIV-1 and feline immuno-deficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases. Journal of Molecular Biology 278:757-765.
2. Balzarini J, Pérez-Pérez MJ, San-Félix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ & De Clercq E (1992) 2′,5′- Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino- 1″,2″-oxathiole-2″,2-dioxide) pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA 89:4392-4396.
3. Balzarini J, Karlsson A, Vandamme AM, Pérez-Pérez MJ, Zhang H, Vrang L, Oberg B, Backbro K, Unge T, San-Félix A, Velázquez S, Camarasa MJ & De Clercq E (1993a) Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)] -β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proceedings of the National Academy of Sciences, USA 90:6952-6956.
4. Balzarini J, Naesens L, Bohman C, Pérez-Pérez MJ, San-Félix A, Camarasa MJ & De Clercq E (1993b) Metabolism and pharmacokinetics of the anti_HIV-1-specific inhibitor [1-[2′,5′-bis- O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3-N-methyl-thymine] -3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide). Biochemical Pharmacology 46:69-77.
5. Balzarini J, Kleim JP, Riess G, Camarasa MJ, De Clercq E & Karlsson A (1994) Sensitivity of (138 Glu → Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochemical & Biophyical Research Communications 201:1305-1312.
6. Balzarini J & De Clercq E (1996) Analysis of inhibition of retroviral reverse transcriptase. Methods in Enzymology 275:472-502.
7. Balzarini J, Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Velázquez S, Perno CF, De Clecq E, Anderson JN & Karlsson A (2001) Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. Journal of Virology 75:5772-5777.
8. Basavapathruni A, Bailey CM & Anderson KS (2004) Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. Journal of Biological Chemistry 279:6221-6224.
9. Basu A, Basu S & Modak MJ (1992) Structure-activity analyses of HIV-1 reverse transcriptase. Biochemical & Biophysical Research Communications 183:1131-1138.
10. Boyer PL, Ding J, Arnold E & Hughes SH (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 38:1909-1914.
11. Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Balzarini J & De Clercq E (1992) 3′-Spironucleosides a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo and ribofuranose]-3′-spiro-5″-[4″-amino-1″, 2″-oxathiole-2″,2″-dioxide] (TSAO) pyrimidine nucleosides. Journal of Medicinal Chemistry 35:2721-2727.
12. Camarasa MJ, San-Félix A, Velázquez S, Pérez- Pérez MJ, Gago F & Balzarini J (2004) TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Current Topics in Medicinal Chemistry 4:945-963.
13. De Castro S, Lobatón E, Pérez-Pérez MJ, San-Félix A, Cordeiro A, Andrei G, Snoeck R, De Clercq E, Balzarini J, Camarasa MJ & and Velázquez S (2005) Novel TSAO derivatives with dual anti HIV-1 and HCMV activity. Journal of Medicinal Chemistry 48:1158-1168.
14. Divita G, Restle T & Goody RS (1993) Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Letters 324:153-158.
15. Divita G, Rittinger K, Geourjon C, Deléage G & Goody RS (1995) Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. Journal of Molecular Biology 245:508-521.
16. Harris D, Lee R, Misra HS, Pandey PK & Pandey VN (1998) The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 37:5903-5908.
17. Hsiou Y, Ding J, Das K, Clark AD Jr, Hughes SH & Arnold E (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4:853-860.
18. Huang H, Chopra R, Verdine GL & Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
19. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, Hizi A, Hughes SH & Arnold E (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proceedings of the National Academy of Sciences, USA 90:6320-6324.
20. Jonckheere H, Taymans JM, Balzarini J, Velázquez S, Camarasa MJ, Desmyter J, De Clercq E & Anne J (1994) Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)- 3′-spiro-5′-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide)] (TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunit. Journal of Biological Chemistry 269:25255-25258.
21. Katz RA & Skalka AM (1994) The retroviral enzymes. Annual Review of Biochemistry 63:133-173.
22. Kohlstaedt LA, Wang J, Fiedman JM, Rice PA & Steitz TA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
23. Lobaton E, Velázquez S, San-Félix A, De Clercq E, Balzarini J & Camarasa MJ (2001) 4″-H-TSAO-T a novel prototype in the HIV-1 specific TSAO family. Nucleosides, Nucleotides & Nucleic Acids 20:711-714.
24. Lobatón, E, Rodríguez-Barrios F, Gago F, Pérez-Pérez MJ, De Clercq E, Balzarini J, Camarasa MJ & Velázquez S. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. Journal of Medicinal Chemistry 45:3934-3945.
25. Müller B, Restle T, Weiss S, Gautel M, Sczakiel G & Goody RS (1989) Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. Journal of Biological Chemistry 264:13975-13978.
26. Pandey PK, Kaushik N, Talele TT, Yadav PNS & Pandey VN (2001) The β7-β8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 40:9505-9512.
27. Pandey PK, Kaushik N, Singh K, Sharma B, Upadhyay AK, Kumar S, Harris D & Pandey VN (2002) Insertion of a small peptide of six amino acids into the β7-β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochemistry 3:18-31.
28. Pelemans H, Aertsen A, Van Laethem K, Vandamme AM, De Clercq E, Pérez-Pérez MJ, San Félix A, Velázquez S, Camarasa MJ & Balzarini J (2001) Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology 280:97-106.
29. Peletskaya EN, Kogon M, Tuske S, Arnold E & Hughes SH (2004) Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. Journal of Virology 78:3387-3397.
30. Pérez-Pérez MJ, San-Félix A & Camarasa MJ (1992a) Synthesis of (1-[2′,5′-bis-O-(tert-butyldimethylsilyl)- β-D-xylo- and β-D-ribofuranosyl]thymine}-3′-spiro-5″- {4″-amino-1″,2″-oxathiole-2″,2″-dioxide} (TSAO). A novel type of specific anti-HIV agents. Tetrahedron Letters 33:3029-3032.
31. Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E & Camarasa MJ (1992b) TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)- β-D-ribofuranosyl]-3′-spiro-(5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. Journal of Medicinal Chemistry 35:2988-2995.
32. Rattner L, Haseltine W, Patarca R, Livak KW, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway Jr, SR, Pearson ML, Lautenberg JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC & Wong-Staal F (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
33. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D & Stammers D (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Structural Biology 2:293-302.
34. Restle T, Müller B & Goody RS (1990) Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. Journal of Biological Chemistry 265:8986-8988.
35. Restle T, Müller B & Goody RS (1992) RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Letters 300:97-100.
36. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C & Harrison SC (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 92:1222-1226.
37. Rodríguez-Barrios F, Pérez C, Lobatón E, Velázquez S, Chamorro C, San-Félix A, Pérez-Pérez MJ, Camarasa MJ, Pelemans H, Balzarini J & Gago F (2001) Identification of a putative binding site for [2′,5′-Bis-O-(tert-butyldimethylsilyl)- β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV1 reverse transcriptase. Journal of Medicinal Chemistry 44:1853-1865.
38. Shen L, Shen J, Luo X, Cheng F, Xu Y, Chen K, Arnold E, Ding J & Jiang H (2003) Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophysical Journal 84:3547-3563.
39. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ & Parniak MA (2000) Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″-dioxo-1″, 2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39:1427-1433.
40. Temiz NA & Bahar I (2002) Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 49:61-70.
41. Vaishnav YN & Wong-Staal F (1991) The biochemistry of AIDS. Annual Review of Biochemistry 60:577-630.
42. Wang J, Smerdon SJ, Jager J, Kohlstaedt LA, Rice PA, Friedman JM & Steitz TA (1994) Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proceedings of the National Academy of Sciences, USA 91:7242-7246.